Interestingly, by using small interfering RNA to knockdown either HSP90α or HSP90β, there was no apparent effect on the survival of the metastatic OSCC cells; however, the simultaneous knockdown of HSP90α and HSP90β significantly reduced their survival [24], demonstrating that TDE-enclosed HSP90 may be a potential prognostic biomarker and therapeutic target in OSCC with lymph node metastasis. This evidence concerns the gene HSP90AB1 and metastatic malignant neoplasm in the lymph nodes.